Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MRK

This Merck (MRK) Stock Bullish Diagonal Trade Targets a Price of $130 by June 18

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Barchart

Merck & Co.'s Quarterly Earnings Preview: What You Need to Know

Merck & Co. is expected to unveil its first-quarter results later this month, and analysts are projecting a triple-digit decline in profit.

Barchart

Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

How Is Merck & Co.'s Stock Performance Compared to Other Healthcare Stocks?

Despite Merck & Co.’s strong performance relative to its peers over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects

Barchart

Merck & Co. Stock Outlook: Is Wall Street Bullish or Bearish?

Merck & Co. has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

3 “Forever Stocks” to Hold When the Market Won’t Sit Still

Chevron, Colgate-Palmolive, and Merck highlight how dividends, durable businesses, and long-term growth drivers can support a buy-and-hold investment strategy

MarketBeat

Merck & Co.'s Q4 2025 Earnings: What to Expect

Merck & Co. will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now

Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.

Barchart

2 Dividend Stocks to Buy Now for Big Payout Growth Ahead

Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.

Barchart

Healthcare Rotation Underway: 3 Stocks Leading the Charge

Are healthcare stocks finally back in fashion? After years of underperformance, a healthcare rotation is underway, led by these three innovative drug makers.

MarketBeat

Merck Makes Big Bet On Flu Protection With Cidara Buyout

Merck Co. Inc. (NYSE:MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ:CDTX) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.

Benzinga

Are Wall Street Analysts Predicting Merck & Co. Stock Will Climb or Sink?

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

On Tuesday, Merck Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib).

Benzinga

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients

Merck Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s (OTC:RHHBY) Avastin (bevacizumab).

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

Barchart

Merck & Co. Earnings Preview: What to Expect

Healthcare giant Merck & Co. is gearing up to unveil its third-quarter results by the end of October, and analysts expect a massive surge in earnings.

Benzinga

Merck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients

Merck Co. Inc. (NYSE:MRK) announced results Tuesday from its Phase 3 HYPERION trial evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) II or III at intermediate or high risk of disease progression.

Benzinga

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Clears Merck's One-Minute Cancer Shot

The U.S. Food and Drug Administration (FDA) on Friday approved Merck Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for Keytruda.

Benzinga

Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug

On Friday, a European agency adopted two positive opinions for Merck Co. Inc.’s (NYSE:MRK) Keytruda (pembrolizumab).

Benzinga

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

Benzinga

Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs

The U.K. faces a growing risk of losing pharmaceutical investment. That’s according to Oxford professor John Bell, a scientist who was involved in coordinating government and industry efforts during the COVID-19 vaccine rollout.

Benzinga

Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data

Merck Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference.

Benzinga

FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck Co. Inc.’s (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab), for the first-line treatment of unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation…

Benzinga

This Merck Pill Promises Powerful Cholesterol Reduction Without Injections

Merck Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance).

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

314 stories

Merck

294 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.